Book Text

REFERENCES

751. Schaner PJ, Brown RL, Kirksey TD, et al: Succinylcholine-induced hyperkalemia in burned patients. 1. Anesth Analg 48:764–770, 1969.

752. Belin RP, Karleen CI: Cardiac arrest in the burned patient following succinyldicholine administration. Anesthesiology 27:516–518, 1966.

753. Viby-Mogensen J, Hanel HK, Hansen E, et al: Serum cholinesterase activity in burned patients. II: Anaesthesia, suxamethonium and hyperkalaemia. Acta Anaesthesiol Scand 19:169–179, 1975.

754. Martyn JA, White DA, Gronert GA, et al: Up-and-down regulation of skeletal muscle acetylcholine receptors. Effects on neuromuscular blockers. Anesthesiology 76:822–843, 1992.

755. Bishop MJ: Hemodynamic and gas exchange effects of pancuronium bromide in sedated patients with respiratory failure. Anesthesiology 60:369–371, 1984.

756. Coggeshall JW, Marini JJ, Newman JH: Improved oxygenation after muscle relaxation in adult respiratory distress syndrome. Arch Intern Med 145:1718–1720, 1985.

757. Conti G, Vilardi V, Rocco M, et al: Paralysis has no effect on chest wall and respiratory system mechanics of mechanically ventilated, sedated patients. Intensive Care Med 21:808–812, 1995.

758. Murray MJ, Cowen J, DeBlock H, et al: Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med 30:142–156, 2002.

759. Hansen-Flaschen JH, Brazinsky S, Basile C, Lanken PN: Use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation for respiratory failure. A national survey. JAMA 266:2870–2875, 1991.

760. Klessig HT, Geiger HJ, Murray MJ, et al: A national survey on the practice patterns of anesthesiologist intensivists in the use of muscle relaxants. Crit Care Med 20:1341–1345, 1992.

761. Parker MM, Schubert W, Shelhamer JH, et al: Perceptions of a critically ill patient experiencing therapeutic paralysis in an ICU. Crit Care Med 12:69–71, 1984.

762. Loper KA, Butler S, Nessly M, et al: Paralyzed with pain: The need for education. Pain 37:315–316, 1989.

763. Hallenberg B, Bergbom-Engberg I, Haljamae H: Patients' experiences of postoperative respirator treatment—influence of anaesthetic and pain treatment regimens. Acta Anaesthesiol Scand 34:557–562, 1990.

764. Merriman HM: The techniques used to sedate ventilated patients. A survey of methods used in 34 ICUs in Great Britain. Intensive Care Med 7:217–224, 1981.

765. Bion JF, Ledingham IM: Sedation in intensive care—a postal survey. Intensive Care Med 13:215–216, 1987.

766. Pollard BJ: Muscle relaxants in critical care. Br J Intensive Care 4:347–353, 1994.

767. Lacomis D, Petrella JT, Giuliani MJ: Causes of neuromuscular weakness in the intensive care unit: A study of ninety-two patients. Muscle Nerve 21:610–617, 1998.

768. Hund EF: Neuromuscular complications in the ICU: The spectrum of critical illness-related conditions causing muscular weakness and weaning failure. J Neurol Sci 136:10–16, 1996.

769. Vianna LG, Koulouris N, Lanigan C, et al: Effect of acute hypercapnia on limb muscle contractility in humans. J Appl Physiol 69:1486–1493, 1990.

770. Coakley JH, Nagendran K, Honavar M, et al: Preliminary observations on the neuromuscular abnormalities in patients with organ failure and sepsis. Intensive Care Med 19:323–328, 1993.

771. De Jonghe B, Sharshar T, Lefaucheur JP, et al: Paresis acquired in the intensive care unit: A prospective multicenter study. JAMA 288:2859–2867, 2002.

772. Rudis MI, Guslits BJ, Peterson EL, et al: Economic impact of prolonged motor weakness complicating neuromuscular blockade in the intensive care unit. Crit Care Med 24:1749–1756, 1996.

773. Lacomis D, Zochodne DW, Bird SJ: Critical illness myopathy. Muscle Nerve 23:1785–1788, 2000.

774. Showalter CJ, Engel AG: Acute quadriplegic myopathy: Analysis of myosin isoforms and evidence for calpain-mediated proteolysis. Muscle Nerve 20:316–322, 1997.

775. Zochodne DW, Ramsay DA, Saly V, et al: Acute necrotizing myopathy of intensive care: Electrophysiological studies. Muscle Nerve 17:285–292, 1994.

776. Douglass JA, Tuxen DV, Horne M, et al: Myopathy in severe asthma. Am Rev Respir Dis 146:517–519, 1992.

777. Kupfer Y, Okrent DG, Twersky RA, et al: Disuse atrophy in a ventilated patient with status asthmaticus receiving neuromuscular blockade. Crit Care Med 15:795–796, 1987.

778. Shee CD: Risk factors for hydrocortisone myopathy in acute severe asthma. Respir Med 84:229–233, 1990.

779. Griffin D, Fairman N, Coursin D, et al: Acute myopathy during treatment of status asthmaticus with corticosteroids and steroidal muscle relaxants. Chest 102:510–514, 1992.

780. Williams TJ, O'Hehir RE, Czarny D, et al: Acute myopathy in severe acute asthma treated with intravenously administered corticosteroids. Am Rev Respir Dis 137:460–463, 1988.

781. Hanson P, Dive A, Brucher JM, et al: Acute corticosteroid myopathy in intensive care patients. Muscle Nerve 20:1371–1380, 1997.

782. Decramer M, de Bock V, Dom R: Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 153:1958–1964, 1996.

783. Deconinck N, Van Parijs V, Beckers-Bleukx G, et al: Critical illness myopathy unrelated to corticosteroids or neuromuscular blocking agents. Neuromuscul Disord 8:186–192, 1998.

784. DuBois DC, Almon RR: Disuse atrophy of skeletal muscle is associated with an increase in number of glucocorticoid receptors. Endocrinology 107:1649–1651, 1980.

565

785. Hund E: Myopathy in critically ill patients. Crit Care Med 27:2544–2547, 1999.

786. Neviere R, Mathieu D, Chagnon JL, et al: Skeletal muscle microvascular blood flow and oxygen transport in patients with severe sepsis. Am J Respir Crit Care Med 153:191–195, 1996.

787. Tsukagoshi H, Morita T, Takahashi K, et al: Cecal ligation and puncture peritonitis model shows decreased nicotinic acetylcholine receptor numbers in rat muscle: Immunopathologic mechanisms? Anesthesiology 91:448–460, 1999.

788. De Letter MA, van Doorn PA, Savelkoul HF, et al: Critical illness polyneuropathy and myopathy (CIPNM): Evidence for local immune activation by cytokine-expression in the muscle tissue. J Neuroimmunol 106:206–213, 2000.

789. Zochodne DW, Bolton CF, Wells GA, et al: Critical illness polyneuropathy. A complication of sepsis and multiple organ failure. Brain 110(Pt 4):819–841, 1987.

790. Berek K, Margreiter J, Willeit J, et al: Polyneuropathies in critically ill patients: A prospective evaluation. Intensive Care Med 22:849–855, 1996.

791. Bolton CF, Breuer AC: Critical illness polyneuropathy. Muscle Nerve 22:419–424, 1999.

792. Tepper M, Rakic S, Haas JA, et al: Incidence and onset of critical illness polyneuropathy in patients with septic shock. Neth J Med 56:211–214, 2000.

793. Bolton CF: Sepsis and the systemic inflammatory response syndrome: Neuromuscular manifestations. Crit Care Med 24:1408–1416, 1996.

794. Mohr M, Englisch L, Roth A, et al: Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive Care Med 23:1144–1149, 1997.

795. Rogers BC: Development of recombinant human nerve growth factor (rhNGF) as a treatment for peripheral neuropathic disease. Neurotoxicology 17:865–870, 1996.

796. van den Berghe G, Wouters P, Weekers F, et al: Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359–1367, 2001.

797. Lorin S, Nierman DM: Critical illness neuromuscular abnormalities. Crit Care Clin 18:553–568, 2002.

798. Leijten FS, de Weerd AW: Critical illness polyneuropathy. A review of the literature, definition and pathophysiology. Clin Neurol Neurosurg 96:10–19, 1994.

799. Zifko UA: Long-term outcome of critical illness polyneuropathy. Muscle Nerve Suppl 9:S49–S52, 2000.

800. Chang CC, Chuang ST, Huang MC: Effects of chronic treatment with various neuromuscular blocking agents on the number and distribution of acetylcholine receptors in the rat diaphragm. J Physiol 250:161–173, 1975.

801. Berg DK, Hall ZW: Increased extrajunctional acetylcholine sensitivity produced by chronic acetylcholine sensitivity produced by chronic post-synaptic neuromuscular blockade. J Physiol 244:659–676, 1975.

802. Hogue CW Jr, Ward JM, Itani MS, et al: Tolerance and upregulation of acetylcholine receptors follow chronic infusion of d-tubocurarine. J Appl Physiol 72:1326–1331, 1992.

803. Dodson BA, Kelly BJ, Braswell LM, et al: Changes in acetylcholine receptor number in muscle from critically ill patients receiving muscle relaxants: An investigation of the molecular mechanism of prolonged paralysis. Crit Care Med 23:815–821, 1995.

804. Hansen D: Suxamethonium-induced cardiac arrest and death following 5 days of immobilization. Eur J Anaesthesiol 15:240–241, 1998.

805. Callanan DL: Development of resistance to pancuronium in adult respiratory distress syndrome. Anesth Analg 64:1126–1128, 1985.

806. Coursin DB, Klasek G, Goelzer SL: Increased requirements for continuously infused vecuronium in critically ill patients. Anesth Analg 69:518–521, 1989.

807. Kushimo OT, Darowski MJ, Morris P, et al: Dose requirements of atracurium in paediatric intensive care patients. Br J Anaesth 67:781–783, 1991.

808. Hughes M, Grant IS, Biccard B, et al: Suxamethonium and critical illness polyneuropathy. Anaesth Intensive Care 27:636–638, 1999.

809. Kupfer Y, Namba T, Kaldawi E, et al: Prolonged weakness after long-term infusion of vecuronium bromide. Ann Intern Med 117:484–486, 1992.

810. Op de Coul AA, Lambregts PC, Koeman J, et al: Neuromuscular complications in patients given Pavulon (pancuronium bromide) during artificial ventilation. Clin Neurol Neurosurg 87:17–22, 1985.

811. Tousignant CP, Bevan DR, Eisen AA, et al: Acute quadriparesis in an asthmatic treated with atracurium. Can J Anaesth 42:224–227, 1995.

812. Gwinnutt CL, Eddleston JM, Edwards D, et al: Concentrations of atracurium and laudanosine in cerebrospinal fluid and plasma in three intensive care patients. Br J Anaesth 65:829–832, 1990.

813. Szenohradszky J, Trevor AJ, Bickler P, et al: Central nervous system effects of intrathecal muscle relaxants in rats. Anesth Analg 76:1304–1309, 1993.

814. Griffiths RB, Hunter JM, Jones RS: Atracurium infusions in patients with renal failure on an ITU. Anaesthesia 41:375–381, 1986.

815. Beemer GH, Dawson PJ, Bjorksten AR, et al: Early postoperative seizures in neurosurgical patients administered atracurium and isoflurane. Anaesth Intensive Care 17:504–509, 1989.

816. Eddleston JM, Harper NJ, Pollard BJ, et al: Concentrations of atracurium and laudanosine in cerebrospinal fluid and plasma during intracranial surgery. Br J Anaesth 63:525–530, 1989.

817. Chiodini F, Charpantier E, Muller D, et al: Blockade and activation of the human neuronal nicotinic acetylcholine receptors by atracurium and laudanosine. Anesthesiology 94:643–651, 2001.

818. Newman PJ, Quinn AC, Grounds RM, et al: A comparison of cisatracurium (51W89) and atracurium by infusion in critically ill patients. Crit Care Med 25:1139–1142, 1997.

819. Dear GJ, Harrelson JC, Jones AE, et al: Identification of urinary and biliary conjugated metabolites of the neuromuscular blocker 51W89 by liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom 9:1457–1464, 1995.

820. Kane SL, Dasta JF: Clinical outcomes of critical illness polyneuropathy. Pharmacotherapy 22:373–379, 2002.

821. Kindler CH, Verotta D, Gray AT, et al: Additive inhibition of nicotinic acetylcholine receptors by corticosteroids and the neuromuscular blocking drug vecuronium. Anesthesiology 92:821–832, 2000.

822. Prielipp RC, Coursin DB, Scuderi PE, et al: Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients. Anesth Analg 81:3–12, 1995.

823. Zarowitz BJ, Rudis MI, Lai K, et al: Retrospective pharmacoeconomic evaluation of dosing vecuronium by peripheral nerve stimulation versus standard clinical assessment in critically ill patients. Pharmacotherapy 17:327–332, 1997.

824. Kress JP, Pohlman AS, O'Connor MF, et al: Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 342:1471–1477, 2000.

825. Noseworthy JH: Progress in determining the causes and treatment of multiple sclerosis. Nature 399:A40–A47, 1999.

826. Meinl E: Concepts of viral pathogenesis of multiple sclerosis. Curr Opin Neurol 12:303–307, 1999.

827. Waxman SG: Do 'demyelinating' diseases involve more than myelin? Nat Med 6:738–739, 2000.

828. Hawkes CH: Is multiple sclerosis a sexually transmitted infection? J Neurol Neurosurg Psychiatry 73:439–443, 2002.

829. Oksenberg JR, Barcellos LF: The complex genetic aetiology of multiple sclerosis. J Neurovirol 6(Suppl 2):S10–S14, 2000.

830. Jacobsen M, Schweer D, Ziegler A, et al: A point mutation in PTPRC is associated with the development of multiple sclerosis. Nat Genet 26:495–499, 2000.

566

831. Steinman L: Multiple sclerosis: A two-stage disease. Nat Immunol 2:762–764, 2001.

832. Lassmann H, Bruck W, Lucchinetti C: Heterogeneity of multiple sclerosis pathogenesis: Implications for diagnosis and therapy. Trends Mol Med 7:115–121, 2001.

833. Aulkemeyer P, Brinkmeier H, Wollinsky KH, et al: The human endogenous local anesthetic-like factor (ELLF) is functionally neutralized by serum albumin. Neurosci Lett 216:37–40, 1996.

834. Brinkmeier H, Seewald MJ, Wollinsky KH, et al: On the nature of endogenous antiexcitatory factors in the cerebrospinal fluid of patients with demyelinating neurological disease. Muscle Nerve 19:54–62, 1996.

835. Brinkmeier H, Wollinsky KH, Seewald MJ, et al: Factors in the cerebrospinal fluid of multiple sclerosis patients interfering with voltage-dependent sodium channels. Neurosci Lett 156:172–175, 1993.

836. Brinkmeier H, Aulkemeyer P, Wollinsky KH, et al: An endogenous pentapeptide acting as a sodium channel blocker in inflammatory autoimmune disorders of the central nervous system. Nat Med 6:808–811, 2000.

837. Kent-Braun JA, Ng AV, Castro M, et al: Strength, skeletal muscle composition, and enzyme activity in multiple sclerosis. J Appl Physiol 83:1998–2004, 1997.

838. Nordenbo AM, Boesen F, Andersen EB: Cardiovascular autonomic function in multiple sclerosis. J Auton Nerv Syst 26:77–84, 1989.

839. Anema JR, Heijenbrok MW, Faes TJ, et al: Cardiovascular autonomic function in multiple sclerosis. J Neurol Sci 104:129–134, 1991.

840. Bannister R, Davies B, Holly E, et al: Defective cardiovascular reflexes and supersensitivity to sympathomimetic drugs in autonomic failure. Brain 102:163–176, 1979.

841. Bader AM, Hunt CO, Datta S, et al: Anesthesia for the obstetric patient with multiple sclerosis. J Clin Anesth 1:21–24, 1988.

842. Siemkowicz E: Multiple sclerosis and surgery. Anaesthesia 31:1211–1216, 1976.

843. Warren TM, Datta S, Ostheimer GW: Lumbar epidural anesthesia in a patient with multiple sclerosis. Anesth Analg 61:1022–1023, 1982.

844. Patten BM, Hart A, Lovelace R: Multiple sclerosis associated with defects in neuromuscular transmission. J Neurol Neurosurg Psychiatry 35:385–394, 1972.

845. Albuquerque EX, McIsaac RJ: Fast and slow mammalian muscles after denervation. Exp Neurol 26:183–202, 1970.

846. McArdle JJ, Michelson L, D'Alonzo AJ: Action potentials in fast- and slow-twitch mammalian muscles during reinnervation and development. J Gen Physiol 75:655–672, 1980.

847. Martin LJ, Price AC, Kaiser A, et al: Mechanisms for neuronal degeneration in amyotrophic lateral sclerosis and in models of motor neuron death (review). Int J Mol Med 5:3–13, 2000.

848. Robberecht W: Oxidative stress in amyotrophic lateral sclerosis. J Neurol 247(Suppl 1):I1–I6, 2000.

849. Rowland LP, Shneider NA: Amyotrophic lateral sclerosis. N Engl J Med 344:1688–1700, 2001.

850. Menzies FM, Ince PG, Shaw PJ: Mitochondrial involvement in amyotrophic lateral sclerosis. Neurochem Int 40:543–551, 2002.

851. Hugon J: ALS therapy: Targets for the future. Neurology 47(6 Suppl 4):S251–S254, 1996.

852. Oosthuyse B, Moons L, Storkebaum E, et al: Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28:131–138, 2001.

853. Llinas R, Sugimori M, Cherksey BD, et al: IgG from amyotrophic lateral sclerosis patients increases current through P-type calcium channels in mammalian cerebellar Purkinje cells and in isolated channel protein in lipid bilayer. Proc Natl Acad Sci U S A 90:11743–11747, 1993.

854. Steindler DA, Pincus DW: Stem cells and neuropoiesis in the adult human brain. Lancet 359:1047–1054, 2002.

855. Beach TP, Stone WA, Hamelberg W: Circulatory collapse following succinylcholine: Report of a patient with diffuse lower motor neuron disease. Anesth Analg 50:431–437, 1971.

856. Maselli RA, Wollman RL, Leung C, et al: Neuromuscular transmission in amyotrophic lateral sclerosis. Muscle Nerve 16:1193–1203, 1993.

857. Rosenbaum KJ, Neigh JL, Strobel GE: Sensitivity to nondepolarizing muscle relaxants in amyotrophic lateral sclerosis: Report of two cases. Anesthesiology 35:638–641, 1971.

858. Serisier DE, Mastaglia FL, Gibson GJ: Respiratory muscle function and ventilatory control. I in patients with motor neurone disease. II in patients with myotonic dystrophy. Q J Med 51:205–226, 1982.

859. Arnulf I, Similowski T, Salachas F, et al: Sleep disorders and diaphragmatic function in patients with amyotrophic lateral sclerosis. Am J Respir Crit Care Med 161:849–856, 2000.

860. Kochi T, Oka T, Mizuguchi T: Epidural anesthesia for patients with amyotrophic lateral sclerosis. Anesth Analg 68:410–412, 1989.

861. Hara K, Sakura S, Saito Y, et al: Epidural anesthesia and pulmonary function in a patient with amyotrophic lateral sclerosis. Anesth Analg 83:878–879, 1996.

862. Kawata A, Kato S, Hayashi H, et al: Prominent sensory and autonomic disturbances in familial amyotrophic lateral sclerosis with a Gly93Ser mutation in the SOD1 gene. J Neurol Sci 153:82–85, 1997.

863. Shimizu T, Kawata A, Kato S, et al: Autonomic failure in ALS with a novel SOD1 gene mutation. Neurology 54:1534–1537, 2000.

864. Linden D, Diehl RR, Berlit P: Reduced baroreflex sensitivity and cardiorespiratory transfer in amyotrophic lateral sclerosis. Electroencephalogr Clin Neurophysiol 109:387–390, 1998.

865. Hughes RA, Hadden RD, Gregson NA, et al: Pathogenesis of Guillain-Barré syndrome. J Neuroimmunol 100:74–97, 1999.

866. Ho TW, McKhann GM, Griffin JW: Human autoimmune neuropathies. Annu Rev Neurosci 21:187–226, 1998.

867. Hahn AF: Guillain-Barré syndrome. Lancet 352:635–641, 1998.

868. Buchwald B, Toyka KV, Zielasek J, et al: Neuromuscular blockade by IgG antibodies from patients with Guillain-Barré syndrome: A macro-patch-clamp study. Ann Neurol 44:913–922, 1998.

869. Buchwald B, Bufler J, Carpo M, et al: Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome. Neurology 56:67–74, 2001.

870. Rudnicki S, Vriesendorp F, Koski CL, et al: Electrophysiologic studies in the Guillain-Barré syndrome: Effects of plasma exchange and antibody rebound. Muscle Nerve 15:57–62, 1992.

871. Dalman JE, Verhagen WI: Cardiac arrest in Guillain-Barré syndrome and the use of suxamethonium. Acta Neurol Belg 94:259–261, 1994.

872. Brooks H, Christian AS, May AE: Pregnancy, anaesthesia and Guillain Barré syndrome. Anaesthesia 55:894–898, 2000.

873. Feldman JM: Cardiac arrest after succinylcholine administration in a pregnant patient recovered from Guillain-Barré syndrome. Anesthesiology 72:942–944, 1990.

874. Fiacchino F, Gemma M, Bricchi M, et al: Hypo- and hypersensitivity to vecuronium in a patient with Guillain-Barré syndrome. Anesth Analg 78:187–189, 1994.

875. Zochodne DW: Autonomic involvement in Guillain-Barré syndrome: A review. Muscle Nerve 17:1145–1155, 1994.

876. Minahan RE Jr, Bhardwaj A, Traill TA, et al: Stimulus-evoked sinus arrest in severe Guillain-Barré syndrome: A case report. Neurology 47:1239–1242, 1996.

877. Vassiliev DV, Nystrom EU, Leicht CH: Combined spinal and epidural anesthesia for labor and cesarean delivery in a patient with Guillain-Barré syndrome. Reg Anesth Pain Med 26:174–176, 2001.

878. Steiner I, Argov Z, Cahan C, et al: Guillain-Barré syndrome after epidural anesthesia: Direct nerve root damage may trigger disease. Neurology 35:1473–1475, 1985.

879. Skre H: Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet 6:98–118, 1974.

567

880. Su Y, Brooks DG, Li L, et al: Myelin protein zero gene mutated in Charcot-Marie-Tooth type 1B patients. Proc Natl Acad Sci U S A 90:10856–10860, 1993.

881. Hahn AF, Ainsworth PJ, Naus CC, et al: Clinical and pathological observations in men lacking the gap junction protein connexin 32. Muscle Nerve Suppl 999:S39–S48, 2000.

882. Bergoffen J, Scherer SS, Wang S, et al. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science 262:2039–2042, 1993.

883. Evans WH, Martin PE: Gap junctions: Structure and function (review). Mol Membr Biol 19:121–136, 2002.

884. Dermietzel R: Gap junction wiring: A 'new' principle in cell-to-cell communication in the nervous system? Brain Res Brain Res Rev 26:176–183, 1998.

885. Kotani N, Hirota K, Anzawa N, et al: Motor and sensory disability has a strong relationship to induction dose of thiopental in patients with the hypertropic variety of Charcot-Marie-Tooth syndrome. Anesth Analg 82:182–186, 1996.

886. Brian JE Jr, Boyles GD, Quirk JG Jr, et al: Anesthetic management for cesarean section of a patient with Charcot-Marie-Tooth disease. Anesthesiology 66:410–412, 1987.

887. Rudnik-Schoneborn S, Rohrig D, Nicholson G, et al: Pregnancy and delivery in Charcot-Marie-Tooth disease type 1. Neurology 43:2011–2016, 1993.

888. Nathanson BN, Yu DG, Chan CK: Respiratory muscle weakness in Charcot-Marie-Tooth disease. A field study. Arch Intern Med 149:1389–1391, 1989.

889. Naguib M, Samarkandi AH: Response to atracurium and mivacurium in a patient with Charcot-Marie-Tooth disease. Can J Anaesth 45:56–59, 1998.

890. Baraka AS: Vecuronium neuromuscular block in a patient with Charcot-Marie-Tooth syndrome. Anesth Analg 84:927–928, 1997.

891. Greenberg RS, Parker SD: Anesthetic management for the child with Charcot-Marie-Tooth disease. Anesth Analg 74:305–307, 1992.

892. Antognini JF: Anaesthesia for Charcot-Marie-Tooth disease: A review of 86 cases. Can J Anaesth 39:398–400, 1992.

893. Ducart A, Adnet P, Renaud B, et al: Malignant hyperthermia during sevoflurane administration. Anesth Analg 80:609–611, 1995.

894. Roelofse JA, Shipton EA: Anaesthesia for abdominal hysterectomy in Charcot-Marie-Tooth disease. A case report. S Afr Med J 67:605–606, 1985.

895. Sugino S, Yamazaki Y, Nawa Y, et al: Anesthetic management for a patient with Charcot-Marie-Tooth disease using propofol and nitrous oxide [in Japanese]. Masui 51:1016–1019, 2002.

896. Eichacker PQ, Spiro A, Sherman M, et al: Respiratory muscle dysfunction in hereditary motor sensory neuropathy, type I. Arch Intern Med 148:1739–1740, 1988.

897. Chan CK, Mohsenin V, Loke J, et al: Diaphragmatic dysfunction in siblings with hereditary motor and sensory neuropathy (Charcot-Marie-Tooth disease). Chest 91:567–570, 1987.

898. Tetzlaff JE, Schwendt I: Arrhythmia and Charcot-Marie-Tooth disease during anesthesia. Can J Anaesth 47:829, 2000.

899. Sulica L, Blitzer A, Lovelace RE, et al: Vocal fold paresis of Charcot-Marie-Tooth disease. Ann Otol Rhinol Laryngol 110:1072–1076, 2001.

900. Cuesta A, Pedrola L, Sevilla T, et al: The gene encoding ganglioside-induced differentiation-associated protein 1 is mutated in axonal Charcot-Marie-Tooth type 4A disease. Nat Genet 30:22–25, 2002.